FOCUS-27 Strategy Gains Momentum: How Our 2024 Performance Defied Expectations
Sanofi Navigates Challenging Market with Operational Resilience in 2024
Paris, March 3rd, 2025 - Despite a turbulent economic landscape, Sanofi demonstrates remarkable adaptability in its full-year 2024 financial results, showcasing strategic strength and financial prudence.
Key Financial Highlights
- Net sales declined 10.0% to €911.9 million, reflecting market challenges
- Core EBITDA reached €50.4 million, with a margin of 5.5%
- Production suspension at Brindisi partially impacted overall performance
Strategic Insights
The company's performance was influenced by lower volumes and production disruptions, yet maintained encouraging commercial momentum. The 370 basis point margin reduction primarily stems from unfavorable fixed cost impacts.
Financial Overview
EBITDA stood at €(43.6) million, with significant investments of €87.1 million aimed at long-term strategic positioning and operational enhancement.
Sanofi remains committed to navigating market complexities with resilience and forward-thinking strategies.